Stockreport

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Biofrontera Inc.  (BFRI) 
PDF First Phase 3 PDT study in patients with sBCC in the United States.Primary and secondary endpoints all highly statistically significant pCorrelates to data seen in Europ [Read more]